AUSTIN, TX / ACCESSWIRE / October 16, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will attend the LD Micro Main Event XVII Conference being held at the Luxe Sunset Blvd Hotel in Los Angeles, CA October 29 - 30, 2024.Monogram Chief Financial Officer Noel Knape will conduct in-person one-on-one meetings during the conference to discuss the Company's novel mBôs precision robotic surgical system. Monogram's mBôs precision robotic surgical system is designed to autonomously execute optimized paths for high-precision insertion of its FDA-cleared mPress pre
Company Has 180 Days From Receipt to Produce Additional InformationAUSTIN, TX / ACCESSWIRE / October 3, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced a correction to its press release issued on Wednesday, October 2, 2024, entitled "Monogram Technologies Receives FDA Response for mBôs TKA System" (the "Prior Press Release").In yesterday's prior press release, dated October 2, 2024, it was stated in the subtitle that: "Company to Conduct Clinical Trial to Produce Additional Information Within 180 Days." The Company now clarifies the subti
AUSTIN, TX / ACCESSWIRE / October 2, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, announced today that the Company closed the previously announced 8.00% Series D Convertible Cumulative Preferred Stock (the "Series D Preferred Stock") continuous offering on October 1, 2024. The Company sold 5,790,479 units, with each unit consisting of (a) one share of the Company's Series D Preferred Stock and (b) one common stock purchase warrant to purchase one share of the Company's common stock, $0.001 par value per share (the "Common Stock"), for a total of 5,790
Company to Conduct Clinical Trial to Produce Additional Information Within 180 DaysAUSTIN, TX / ACCESSWIRE / October 2, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced that it has received an Additional Information Request ("AIR") from the U.S. Food and Drug Administration ("FDA") on September 30, 2024, regarding its 510(k) premarket filing submission for the Company's mBôs TKA System (the "Application").The Application was submitted on July 19, 2024, and passed the initial FDA Administrative Review. The FDA informed the Company that the
AUSTIN, TX / ACCESSWIRE / October 1, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, announced today the declaration of a dividend of $0.0255 per share payable to holders of record of shares of the Company's 8.00% Series D Convertible Cumulative Preferred Stock (the "Series D Preferred Stock") at the close of business on October 1, 2024. In addition, the Company announced that it will be paying the dividend in kind based on the closing price of its common stock, par value $0.001 per share on September 30, 2024. Holders of record will receive the dividend
AUSTIN, TX / ACCESSWIRE / September 11, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced an upsize of its previously announced continuous offering of units from $10 million to $12.5 million of units. Each unit consists of (a) one share of the Company's 8.00% Series D Convertible Cumulative Preferred Stock (the "Series D Preferred Stock") and (b) one common stock purchase warrant to purchase one share of its common stock, $0.001 par value per share (the "Common Stock").The units have no stand-alone rights and will not be certified or issued
Submitted FDA 510(k) Application and Passed FDA Administrative Review for the mBôs TKA SystemSecured Initial Strategic Multicenter Clinical Trial Collaboration with Shalby LimitedManagement to Host Business Update Conference Call Today at 4:30 p.m. Eastern Time AUSTIN, TX / ACCESSWIRE / August 14, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the second quarter ended June 30, 2024.Second Quarter 2024 and Subsequent Operational HighlightsSubmitted a 510(k) premarket filing to the U.S. Food and Drug
Clinical Trial Collaboration Follows 510(k) Submission and Passing of FDA Administrative Review; Preludes Planned International Launch for the mBȏs TKA SystemStrategic Partner Shalby is Recognized as one of the Leading Institutions for Orthopedic Surgeries Worldwide, Performing Over 14,000 Annual Knee Replacement Surgeries Globally AUSTIN, TX / ACCESSWIRE / August 12, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced its strategic collaboration with Shalby Limited (NSE:SHALBY) ("Shalby"), a global muti-specialty hospital chain and one of In
Application was Submitted on July 19, 2024, Passed the FDA Administrative Review, and is Now Under Substantive ReviewFDA Decision is Expected Within 90 Days of Initial Submission; However, the Process May be Paused if Additional Information is Requested AUSTIN, TX / ACCESSWIRE / August 8, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced that it has submitted a 510(k) premarket filing to the U.S. Food and Drug Administration (FDA) for the Company's mBôs TKA System. The application was submitted on July 19, 2024, and passed the FDA Administr
AUSTIN, TX / ACCESSWIRE / August 1, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will hold a business update conference call on Wednesday, August 14, 2024 at 4:30 p.m. Eastern Time in conjunction with its reported financial results for the second quarter ended June 30, 2024 and to discuss key milestones. A press release detailing these results will be issued prior to the call.Monogram CEO Ben Sexson and CFO Noel Knape will host the conference call, followed by a question-and-answer session. The conference call will be accompanied by a presentation, wh
AUSTIN, TX / ACCESSWIRE / October 1, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, announced today the declaration of a dividend of $0.0255 per share payable to holders of record of shares of the Company's 8.00% Series D Convertible Cumulative Preferred Stock (the "Series D Preferred Stock") at the close of business on October 1, 2024. In addition, the Company announced that it will be paying the dividend in kind based on the closing price of its common stock, par value $0.001 per share on September 30, 2024. Holders of record will receive the dividend
AUSTIN, TX / ACCESSWIRE / August 1, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will hold a business update conference call on Wednesday, August 14, 2024 at 4:30 p.m. Eastern Time in conjunction with its reported financial results for the second quarter ended June 30, 2024 and to discuss key milestones. A press release detailing these results will be issued prior to the call.Monogram CEO Ben Sexson and CFO Noel Knape will host the conference call, followed by a question-and-answer session. The conference call will be accompanied by a presentation, wh
Verification and Validation Testing Expected to be Largely Complete in Q2 2024; 510(k) Submission with FDA Accelerated for Second Half of 2024Engaged Contract Research Organization to Oversee mBôs Robot Clinical Trial Activities Outside the U.S.Management to Host Business Update Conference Call on Wednesday, May 22 at 4:30 p.m. Eastern Time AUSTIN, TX / ACCESSWIRE / May 14, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the first quarter ended March 31, 2024.First Quarter 2024 and Subsequent Operati
AUSTIN, TX / ACCESSWIRE / March 20, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), a medical technology company focused on reconstructive joint procedures and surgical robotics, today announced management will host a business update conference call on Thursday, March 21, 2024 at 5:00 p.m. Eastern time to discuss its results for the full fiscal year ended December 31, 2023, and will be providing regulatory updates, reviewing ongoing initiatives and technology strategy, and anticipated 2024 milestones.Monogram Chief Executive Officer Ben Sexson, Chief Medical Officer Doug Unis, MD, Chief Technology Officer Kamran Shamaei, and Chief Financial Officer Noel Knape w
510(k) Submission with FDA On Track for Second Half of 2024Shipped mBôs Surgical Robot System to First International CustomerIntroduced mVision Technologies, a Novel Approach to Registration and TrackingManagement to Host Business Update Conference Call on Thursday, March 21 at 5:00 p.m. Eastern TimeAUSTIN, TX / ACCESSWIRE / March 15, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), a medical technology company focused on reconstructive joint procedures and surgical robotics, has reported its financial and operational results for the fourth quarter and full year ended December 31, 2023.Fourth Quarter 2023 and Subsequent Operational HighlightsThe Company's plan t
AUSTIN, TX / ACCESSWIRE / May 23, 2023 / Monogram Orthopaedics Inc., (NASDAQ:MGRM) ("Monogram" or the "Company") a medical technology company focused on reconstructive joint procedures and orthopedic implants, today announced it has engaged international investor relations specialists MZ Group ("MZ") to lead a comprehensive strategic investor relations and financial communications program across all key markets.MZ Group will work closely with Monogram management to develop and implement a comprehensive capital markets strategy designed to increase the Company's visibility throughout the investment community. The campaign will highlight Monogram's work to develop a product solution architectu
PRE 14A - Monogram Technologies Inc. (0001769759) (Filer)
8-K - Monogram Technologies Inc. (0001769759) (Filer)
8-K - Monogram Technologies Inc. (0001769759) (Filer)
424B5 - Monogram Technologies Inc. (0001769759) (Filer)
8-K - Monogram Technologies Inc. (0001769759) (Filer)
8-K - Monogram Technologies Inc. (0001769759) (Filer)
8-K - Monogram Technologies Inc. (0001769759) (Filer)
424B5 - Monogram Technologies Inc. (0001769759) (Filer)
8-K - Monogram Technologies Inc. (0001769759) (Filer)
10-Q - Monogram Technologies Inc. (0001769759) (Filer)
Collaboration to Provide Monogram with Technical Resources to Drive Development and Commercialization of mBôs SystemAUSTIN, TX / ACCESSWIRE / April 11, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), a medical technology company focused on reconstructive joint procedures and surgical robotics, today announced it has joined NVIDIA Inception, a program designed to help companies evolve faster through cutting-edge technology and access to the latest technical resources from NVIDIA.NVIDIA Inception will help drive Monogram to help drive development of its mBôs robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation co
4 - MONOGRAM ORTHOPAEDICS INC (0001769759) (Issuer)
Shares of Pure Storage, Inc. (NYSE:PSTG) rose sharply in today's pre-market trading following better-than-expected first-quarter financial results. Pure Storage reported quarterly earnings of 32 cents per share, which beat the analyst consensus estimate of 21 cents. Quarterly sales clocked in at $693.479 million, beating the analyst consensus estimate of $680.972 million, according to data from Benzinga Pro. Pure Storage shares jumped 10.5% to $69.60 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers Smart for Life, Inc. (NASDAQ:SMFL) rose 60.5% to $6.27 in today's pre-market trading after gaining around 17% on Wednesday. Smart
New Name Reflects Continued Evolution as an AI-Driven Robotics Company with a Strong IP Position
CRO Expands Clinical Capabilities, Accelerating Product Pipeline Development and Commercialization Opportunities
Gainers Monogram Orthopaedics (NASDAQ:MGRM) stock increased by 19.1% to $2.31 during Monday's pre-market session. The company's market cap stands at $73.1 million. Allarity Therapeutics (NASDAQ:ALLR) shares moved upwards by 13.99% to $1.14. The market value of their outstanding shares is at $2.2 million. VYNE Therapeutics (NASDAQ:VYNE) shares increased by 13.74% to $2.98. The company's market cap stands at $42.0 million. Allogene Therapeutics (NASDAQ:ALLO) stock increased by 13.02% to $3.47. The market value of their outstanding shares is at $592.4 million. Sunshine Biopharma (NASDAQ:SBFM) stock rose 12.55% to $0.95. Addex Therapeutics (NASDAQ:ADXN) shares increased by 12.4% to $10.06.
Shares of JPMorgan Chase & Co. (NYSE:JPM) fell sharply during Friday’s session following first-quarter earnings. Net revenue (managed) of $42.5 billion (+8% Y/Y), beating the consensus of $41.8 billion. Excluding an item resulted in an increase of $550 million (after tax) to reported net income from $13.4 billion to $14.0 billion and an increase of $0.19 per share to reported EPS from $4.44 to $4.63. EPS was $4.44, beating the consensus of $4.15. JPMorgan Chase shares dipped 5.1% to $185.49 on Friday. Here are some other stocks moving in today's mid-day session. Gainers PaxMedica, Inc. (NASDAQ:PXMD) jumped 143% to $1.0101 after the company announced the completed execution of its thr
Gainers PaxMedica (NASDAQ:PXMD) stock increased by 110.9% to $0.87 during Friday's regular session. The company's market cap stands at $6.4 million. Q32 Bio (NASDAQ:QTTB) shares rose 23.89% to $29.5. The market value of their outstanding shares is at $351.9 million. Cyclacel Pharmaceuticals (NASDAQ:CYCCP) shares increased by 20.45% to $21.2. SenesTech (NASDAQ:SNES) stock rose 19.95% to $0.89. The market value of their outstanding shares is at $4.5 million. Rani Therapeutics Hldgs (NASDAQ:RANI) shares moved upwards by 17.48% to $5.25. The market value of their outstanding shares is at $136.7 million. Allarity Therapeutics (NASDAQ:ALLR) shares moved upwards by 16.92% to $2.69. The compan
U.S. stocks traded lower this morning, with the Dow Jones index falling around 200 points on Friday. Following the market opening Friday, the Dow traded down 0.54% to 38,249.92 while the NASDAQ fell 0.83% to 16,305.21. The S&P 500 also fell, dropping, 0.62% to 5,166.70. Check This Out: Best Buy, Box And 2 Other Stocks Insiders Are Selling Leading and Lagging Sectors Energy shares rose by 1.1% on Friday. In trading on Friday, information technology shares fell by 1.1%. Top Headline Citigroup Inc (NYSE:C) posted better-than-expected earnings for its first quarter. Citigroup reported a first-quarter fiscal 2024 revenue decline of 2% year-over-year to $21.10 billion, beatin
Gainers PaxMedica (NASDAQ:PXMD) stock moved upwards by 104.2% to $0.84 during Friday's pre-market session. The market value of their outstanding shares is at $6.2 million. Allarity Therapeutics (NASDAQ:ALLR) stock increased by 55.84% to $3.58. The company's market cap stands at $1.6 million. HCW Biologics (NASDAQ:HCWB) shares increased by 20.77% to $1.86. The market value of their outstanding shares is at $70.3 million. Portage Biotech (NASDAQ:PRTG) stock rose 17.6% to $0.59. The company's market cap stands at $11.6 million. PepGen (NASDAQ:PEPG) shares rose 16.75% to $14.84. The company's market cap stands at $480.1 million. Akanda (NASDAQ:AKAN) stock increased by 15.82% to $0.17. The
Shares of NextPlat Corp (NASDAQ:NXPL) rose sharply in today’s pre-market trading after the company reported consolidated 2023 revenues of $37.8 million, up 222% year over year NextPlat shares surged 29.8% to $1.96 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Allarity Therapeutics, Inc. (NASDAQ:ALLR) shares rose 100.8% to $4.62 in pre-market trading after dipping 29% on Thursday. Allarity Therapeutics filed prospectus supplement to increase offering price of common stock that may be offered from $1.4 million to $2.4 million. PaxMedica, Inc. (NASDAQ:PXMD) gained 77.2% to $0.7353 in pre-market trading after the company announced the complete